Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 654
- Registration Number
- NCT06649214
A Study of Olanzapine After Intranasal and Intramuscular Administration
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Neurelis, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06600477
- Locations
- 🇯🇴
International Pharmaceutical Research Center (IPRC) Clinical Site, Amman, Jordan
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 172
- Registration Number
- NCT06588413
- Locations
- 🇺🇸
Wellstar MCG, Augusta, Georgia, United States
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 156
- Registration Number
- NCT06554613
Detoxification From the Lipid Tract
- Conditions
- Interventions
- Device: electroencephalogram biofeedbackDevice: electrical brain stimulationDevice: ultra-low frequency transcranial magnetic stimulationDrug: Sertraline HydrochlorideDrug: ClonazepamDrug: AlprazolamDrug: MetoprololDrug: OlanzapineDrug: Pravastatin Sodium 20 MGDrug: Sacubitril Valsartan Sodium Hydrate
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Pachankis, Yang I., M.D.
- Target Recruit Count
- 1
- Registration Number
- NCT06357104
- Locations
- 🇨🇳
Residential Address, Chongqing, Chongqing, China
NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens
- Conditions
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 627
- Registration Number
- NCT06331520
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT06319170
- Locations
- 🇺🇸
Teva Investigational Site 15730, Los Alamitos, California, United States
🇺🇸Teva Investigational Site 15727, Hollywood, Florida, United States
🇺🇸Teva Investigational Site 15729, Atlanta, Georgia, United States
Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Dr Rabia Arshad
- Target Recruit Count
- 140
- Registration Number
- NCT06200584
- Locations
- 🇵🇰
Jinnah Post Graduate Medical Centre, Karachi, Sindh, Pakistan
Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 87
- Registration Number
- NCT06200181
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Pediatric Oncology Nutrition Intervention Trial
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Corey Hawes
- Target Recruit Count
- 45
- Registration Number
- NCT06175273
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.